NI200900050A - Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato - Google Patents

Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato

Info

Publication number
NI200900050A
NI200900050A NI200900050A NI200900050A NI200900050A NI 200900050 A NI200900050 A NI 200900050A NI 200900050 A NI200900050 A NI 200900050A NI 200900050 A NI200900050 A NI 200900050A NI 200900050 A NI200900050 A NI 200900050A
Authority
NI
Nicaragua
Prior art keywords
chlorophenyl
hydroxy
ethyl carbamate
new crystal
crystal
Prior art date
Application number
NI200900050A
Other languages
English (en)
Inventor
Peterson Matthew
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200900050A publication Critical patent/NI200900050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La presente invención se relaciona a un nuevo cristal de (S)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato, composiciones farmacéuticas que comprenden este cristal y métodos para elaborar y utilizar este cristal.
NI200900050A 2006-10-06 2009-04-03 Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato NI200900050A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06

Publications (1)

Publication Number Publication Date
NI200900050A true NI200900050A (es) 2010-02-01

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900050A NI200900050A (es) 2006-10-06 2009-04-03 Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato

Country Status (19)

Country Link
US (1) US7632963B2 (es)
EP (1) EP2076258A4 (es)
JP (1) JP2010505856A (es)
KR (1) KR20090076958A (es)
CN (1) CN101657195A (es)
AU (1) AU2007307029A1 (es)
BR (1) BRPI0718131A2 (es)
CA (1) CA2665573A1 (es)
CO (1) CO6180504A2 (es)
CR (1) CR10764A (es)
EA (1) EA200970355A1 (es)
GT (1) GT200900076A (es)
IL (1) IL198016A0 (es)
MX (1) MX2009003755A (es)
NI (1) NI200900050A (es)
NO (1) NO20091771L (es)
SV (1) SV2009003211A (es)
WO (1) WO2008045391A2 (es)
ZA (1) ZA200903095B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101862203B1 (ko) * 2011-12-27 2018-05-29 (주)바이오팜솔루션즈 페닐알킬카바메이트 유도체 화합물 및 이를 포함하는 약학 조성물
CA3227793A1 (en) * 2021-08-05 2023-02-09 Yong Moon Choi Phenylcarbamate crystalline form and method for manufacturing the same
KR102399807B1 (ko) 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
CN1176654C (zh) * 1999-09-10 2004-11-24 大日本油墨化学工业株式会社 喹啉酮衍生物制剂及其制法
CA2439295C (en) * 2001-02-27 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
CN100457723C (zh) * 2001-12-21 2009-02-04 奥索-麦克尼尔药品公司 制备氨基甲酸2-(取代苯基)-2-羟基-乙酯的方法
EP1658276B1 (en) * 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
KR20070057939A (ko) * 2004-09-16 2007-06-07 얀센 파마슈티카 엔.브이. 간질형성 및 간질을 치료하는 방법
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
CR10764A (es) 2009-09-14
BRPI0718131A2 (pt) 2013-11-05
EA200970355A1 (ru) 2009-12-30
JP2010505856A (ja) 2010-02-25
EP2076258A2 (en) 2009-07-08
CN101657195A (zh) 2010-02-24
IL198016A0 (en) 2009-12-24
US20080085930A1 (en) 2008-04-10
US7632963B2 (en) 2009-12-15
MX2009003755A (es) 2009-07-10
WO2008045391A3 (en) 2008-06-12
CA2665573A1 (en) 2008-04-17
KR20090076958A (ko) 2009-07-13
GT200900076A (es) 2010-05-18
EP2076258A4 (en) 2011-09-28
WO2008045391A2 (en) 2008-04-17
CO6180504A2 (es) 2010-07-19
AU2007307029A1 (en) 2008-04-17
NO20091771L (no) 2009-05-05
ZA200903095B (en) 2010-07-28
SV2009003211A (es) 2009-11-24

Similar Documents

Publication Publication Date Title
ECSP088854A (es) Moduladores bencimidazolicos de vr1
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
ECSP10010245A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
UY30610A1 (es) Moduladores de mglur5
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
UY30307A1 (es) Moduladores de mglur5 vi
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
ME01459B (me) Postupak za doziranje medikamenata
UY30306A1 (es) Moduladores de mglur5 iii
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
ECSP099389A (es) Nuevas formas cristalinas
UY30309A1 (es) Moduladores de mglur5 ii
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
NI200900050A (es) Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato
UY30801A1 (es) Compuestos calciliticos
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
DK2060578T3 (da) Fremgangsmåde til fremstilling af optisk aktiv aminophosphinylsmørsyre
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina